Aardvark Therapeutics, Inc.
AARD
$5.39
$0.020.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 154.32% | 127.74% | 75.64% | 127.21% | 84.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 175.29% | 243.47% | 235.02% | 295.75% | 207.28% |
| Operating Income | -175.29% | -243.47% | -235.02% | -295.75% | -207.28% |
| Income Before Tax | -179.73% | -252.14% | -211.10% | -252.81% | -185.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -179.73% | -252.14% | -211.10% | -252.81% | -185.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -179.73% | -252.14% | -211.10% | -252.81% | -185.63% |
| EBIT | -175.29% | -243.47% | -235.02% | -295.75% | -207.28% |
| EBITDA | -175.31% | -300.93% | -395.54% | -1,332.29% | -- |
| EPS Basic | 42.96% | -22.79% | -54.17% | -166.79% | -182.04% |
| Normalized Basic EPS | 42.36% | -23.33% | -60.20% | -201.62% | -235.68% |
| EPS Diluted | 42.96% | -22.79% | -54.17% | -166.79% | -182.04% |
| Normalized Diluted EPS | 42.36% | -23.33% | -60.20% | -201.62% | -235.68% |
| Average Basic Shares Outstanding | 390.33% | 281.82% | 170.65% | 59.04% | 0.89% |
| Average Diluted Shares Outstanding | 390.33% | 281.82% | 170.65% | 59.04% | 0.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |